Catalent Pharma Solutions Signs Agreement with ALK-Abello A/S to Expand Zydis Production Capacity  
8/29/2007 7:32:03 AM

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent Pharma Solutions, Inc and Danish pharmaceutical company ALK-Abello A/S have signed an agreement that will enable a substantial increase in Zydis® oral dissolving tablet production capacity dedicated to ALK-Abello's immunotherapy products.

Under the agreement, ALK-Abello will fund a new production line for current and future tablet-based allergy products, which will be based at Catalent's Swindon, United Kingdom facility. Commercial production on the new line is currently expected to begin in 2010.

ALK-Abello has launched GRAZAX®, a tablet-based vaccine against grass pollen allergy, using Catalent's innovative Zydis oral dissolving tablet technology, and Catalent is already producing the Zydis formulation of GRAZAX in the Swindon facility.

"We are pleased to have reached this next important step in our relationship with ALK-Abello, which began more than four years ago," commented Thomas Stuart, group president of Oral Technologies for Catalent. "The clinical success of GRAZAX® demonstrates that protein-based products such as allergens can be taken orally by patients rather than via injection, and we believe Zydis provides unique advantages to deliver these and other types of novel compounds. We look forward to supporting the further success of GRAZAX® and additional ALK-Abello immunotherapy products."

"We are pleased to have reached this agreement with Catalent to provide important new production capacity, which we believe will be required to meet the expected future demand for our tablet-based allergy vaccines," said Jens Bager, president and CEO of ALK-Abello. "We appreciate the consistent performance and dedication of the Catalent team in Swindon, and the valuable contribution the team and the Zydis technology is making to our product."

Catalent is the world leader in providing advanced dose form delivery technologies to the industry. Zydis, Catalent's fast dissolving oral tablet used in GRAZAX, can be swallowed without water and dissolves in the mouth in typically less than three seconds. Zydis offers the potential for added patient and consumer convenience, enhanced drug performance, and improved patient compliance. In addition to the Swindon, United Kingdom facility, Catalent has also recently established commercial-scale Zydis production in New Jersey.

About Catalent

Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is the leading provider of advanced technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 10,000 at more than 30 facilities worldwide and generates more than $1.7 billion of annual revenue. For more information, visit


Catalent Cornell Stamoran, 732-537-6408 or

Peppercom for Catalent Brian Gawron, 212-931-6167

Source: Catalent Pharma Solutions, Inc.